Find a Cancer Provider

Are you a referring physician?
I am searching for a
Reset Form
Jay Fitzgerald Dorsey, MD, PhD

Jay Fitzgerald Dorsey, MD, PhD Physician

Associate Professor of Radiation Oncology

Dr. Dorsey is employed by Penn Medicine.

Clinical Specialties


  • Radiation Oncology

Programs & Centers:

Board Certification:

  • Radiation Oncology, 2009

Clinical Expertise:

  • Brain and Spine Tumors
  • External Beam Radiation Therapy

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Amerihealth
  • NJ Medicaid
  • NJ Medicare
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: University of South Florida
Residency: University of South Florida
Residency: Hospital of the University of Pennsylvania


American Association for Cancer Research (AACR), National American Brain Tumor Association (ABTA), National American Medical Association (AMA), National American Radium Society, National American Society for Radiation Oncology (ASTRO), National American Society of Clinical Oncology (ASCO), International American Society of Clinical Oncology (ASCO), National National Institutes of Health (NIH), National National Institutes of Health, National National Institutes of Health, National Order of the Engineer, Local Radiation Research Society, International Radiological Society of North America (RSNA), National Society for Neuro-Oncology (SNO), International Society for Translational Oncology, International

Hospital Affiliation

Dr. Dorsey is employed by Penn Medicine.

Hospital Privileges:

  • Chester County Hospital: Has privileges to treat patients in the hospital.
  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.


Description of Research Expertise:

As a Physician-Scientist, I conduct brain tumor research and specialize in treatment of patients with intracranial malignancies. I have scientific expertise in the areas of signal transduction, molecular therapeutics, brain tumor biology, and radiation biology. As a translational researcher, I am actively involved in basic mechanistic studies, the application of in vivo imaging methods to preclinical studies in relevant biological models of cancer, and early phase clinical trials in intracranial malignancies. In a broad sense, my research focuses on understanding the underlying mechanisms whereby cancers demonstrate resistance to radiation and chemotherapy. This information will give us a framework to develop ways to target oncogenic pathways that lead to therapeutic resistance and identify potential molecular interventions that may reduce the normal tissue complications of radiation therapy. One research focus concerns the elucidation of mechanism(s) whereby the Integrated Stress Response (ISR) modulates death receptor expression, and leveraging this understanding therapeutically. A second area of focus is the identification and characterization of circulating tumor cells (CTCs) in the peripheral blood of cancer patients including those with primary brain tumors to gain prognostic and predictive information. Finally, my laboratory has an ongoing project focused on the application and preclinical testing of novel theranostic gold nanoparticle agents in the imaging and radiosensitization of tumors and overcoming challenges of therapeutic access through the blood brain barrier. This includes evaluation of the efficacy of novel radiotheranostic nanoparticle combinations in preclinical animal models and determination of timing, dosage, and in vivo mechanisms of anti-tumor action.

Selected Publications:

Baumann BC, Lustig RA, Mazzoni S, Grady SM, O'Malley BW, Lee JYK, Newman JG, Schuster JM, Both S, Lin A, Dorsey JF, Alonso-Basanta M: A prospective clinical trial of proton therapy for chordoma and chondrosarcoma: Feasibility assessment J Surg Oncol. : 2019.

Sheikh Saad, Saxena Deeksha, Tian Xiaobing, Amirshaghaghi Ahmad, Tsourkas Andrew, Brem Steven, Dorsey Jay F: An integrated stress response agent that modulates DR5 dependent TRAIL synergy reduces patient derived glioma stem cell viability. Molecular cancer research : MCR : 2019.

Liu Tianrun, Xu Haineng, Huang Menggui, Ma Wenjuan, Saxena Deeksha, Lustig Robert A, Alonso-Basanta Michelle, Zhang Zhenfeng, O'Rourke Donald M, Zhang Lin, Gong Yanqing, Kao Gary D, Dorsey Jay F, Fan Yi: Circulating Glioma Cells Exhibit Stem Cell-like Properties. Cancer research 78 (23): 6632-6642,2018.

Frick Melissa A, Kao Gary D, Aguarin Louise, Chinniah Chimbu, Swisher-McClure Samuel, Berman Abigail T, Levin William P, Cengel Keith A, DeCesaris Cristina, Hahn Stephen M, Dorsey Jay F, Simone Charles B: Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. International journal of radiation oncology, biology, physics 102 (3): 536-542,2018.

Zeh R, Sheikh S, Xia L, Pierce J, Newton A, Predina J, Cho S, Nasrallah M, Singhal S, Dorsey J, Lee JYK: The second window ICG technique demonstrates a broad plateau period for near infrared fluorescence tumor contrast in glioblastoma PloS One 12 (7): 2017.

Sattiraju A, Xiong X, Pandya DN, Wadas TJ, Xuan A, Sun Y, Jung Y, Solingapuram Sai KK, Dorsey JF, Li KC, Mintz A: Alpha particle enhanced Blood Brain/Tumor Barrier permeabilization in glioblastomas using integrin alpha-v beta-3 targeted liposomes Mol Cancer Ther. : 2017.

Chinniah C, Aguarin L, Cheng P, DeCesaris C, Cutillo A, Berman AT, Frick M, Levin WP, Cengel KA, Hahn SM, Dorsey JF, Kao GD, Simone CB 2nd: Prospective Trial of Circulating Tumor Cells as a Biomarker for Early Detection of Recurrence in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation Therapy Int J Radiat Oncol Biol Phys. 98 (1): 2017.

Sattiraju Anirudh, Xiong Xiaobing, Pandya Darpan N, Wadas Thaddeus J, Xuan Ang, Sun Yao, Jung Youngkyoo, Sai Kiran Kumar Solingapuram, Dorsey Jay F, Li King C, Mintz Akiva: Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes. Molecular cancer therapeutics 16 (10): 2191-2200,2017.

Sun Lova, Joh Daniel Y, Al-Zaki Ajlan, Stangl Melissa, Murty Surya, Davis James J, Baumann Brian C, Alonso-Basanta Michelle, Kaol Gary D, Tsourkas Andrew, Dorsey Jay F: Theranostic Application of Mixed Gold and Superparamagnetic Iron Oxide Nanoparticle Micelles in Glioblastoma Multiforme. J Biomed Nanotechnol 12 (2): 347-56,2016.

Xu Melody J, Dorsey Jay F, Amaravadi Ravi, Karakousis Giorgos, Simone Charles B, Xu Xiaowei, Xu Wei, Carpenter Erica L, Schuchter Lynn, Kao Gary D: Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. Theoncologist 21 (1): 84-94,2016.

View all publications

Academic Contact Info

Department of Radiation Oncology
Perelman Center for Advanced Medicine
Bldg 421 SCTR 8-135
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 662-2428
Patient appointments: 800-789-7366 (PENN)

Related Links